By Alex Philippidis

NEW YORK (GenomeWeb News) – The Minnesota Partnership for Biotechnology and Medical Genomics plans to lead a multi-institutional effort to translate diabetes research into improved yet lower-cost treatments, if not a cure, for the disease within 10 years – an effort it projects will require between $250 million and $350 million of public and private funds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.